RESPIRATORY DEPRESSION Fatal respiratory depression has occurred in patients treated with immediate-release transmucosal fentanyl, including following use in opioid non-tolerant patients and improper dosing. The substitution of ABSTRAL for any other fentanyl product may result in fatal overdose. Due to the risk of respiratory depression, ABSTRAL is contraindicated in the management of acute or postoperative pain i...
ABSTRAL (fentanyl) sublingual tablets are indicated for the management of breakthrough pain in cancer patients 18 years of age and older who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain. Patients considered opioid tolerant are those who are taking around-theclock medicine consisting of at least 60 mg of oral morphine daily, or at least 25 mcg of transderm...
Healthcare professionals who prescribe ABSTRAL on an outpatient basis must enroll in the TIRF REMS Access program and comply with the requirements of the REMS to ensure safe use of ABSTRAL [See Warnings and Precautions ( 5.10 )]. As with all opioids, the safety of patients using such products is dependent on health care professionals prescribing them in strict conformity with their approved labeling with respect t...
ABSTRAL is supplied in individually sealed child-resistant blister packages contained in a cardboard outer carton, in pack sizes of 12 (100 mcg, 200 mcg, 300 mcg and 400 mcg strengths) or 32 (all strengths) tablets. The packaging is color-coded for each ABSTRAL tablet strength. The amount of fentanyl contained in ABSTRAL can be fatal to a child, individual for whom it is not prescribed or non-opioid tolerant adult...
www.TIRFREMSAccess.com
www.fda.govRESPIRATORY DEPRESSION
Fatal respiratory depression has occurred in patients treated with immediate-release transmucosal fentanyl, including following use in opioid non-tolerant patients and improper dosing. The substitution of ABSTRAL for any other fentanyl product may result in fatal overdose.
Due to the risk of respiratory depression, ABSTRAL is contraindicated in the management of acute or postoperative pain including headache/migraine and in opioid non-tolerant patients. [see Contraindications (4)]
ABSTRAL must be kept out of reach of children. [see Patient Counseling Information (17.1) and How Supplied/Storage and Handling (16.1)]
The concomitant use of ABSTRAL with CYP3A4 inhibitors may result in an increase in fentanyl plasma concentrations, and may cause potentially fatal respiratory depression. [see Drug Interactions (7)]
MEDICATION ERRORS
Substantial differences exist in the pharmacokinetic profile of ABSTRAL compared to other fentanyl products that result in clinically important differences in the extent of absorption of fentanyl that could result in fatal overdose.
ABUSE POTENTIAL
ABSTRAL contains fentanyl, an opioid agonist and a Schedule II controlled substance, with an abuse liability similar to other opioid analgesics. ABSTRAL can be abused in a manner similar to other opioid agonists, legal or illicit. This should be considered when prescribing or dispensing ABSTRAL in situations where the physician or pharmacist is concerned about an increased risk of misuse, abuse or diversion.
Because of the risk for misuse, abuse, addiction, and overdose, ABSTRAL is available only through a restricted program, required by the Food and Drug Administration, called a Risk Evaluation and Mitigation Strategy (REMS). Under the TIRF (Transmucosal Immediate Release Fentanyl) REMS Access program, outpatients, healthcare professionals who prescribe to outpatients, pharmacies, and distributors must enroll in the program [see Warnings and Precautions (5.10)]. Further information is available at www.TIRFREMSAccess.com or by calling1-866-822-1483.
ABSTRAL (fentanyl) sublingual tablets are indicated for the management of breakthrough pain in cancer patients 18 years of age and older who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain. Patients considered opioid tolerant are those who are taking around-theclock medicine consisting of at least 60 mg of oral morphine daily, or at least 25 mcg of transdermal fentanyl/hour, or at least 30 mg of oral oxycodone daily, or at least 8 mg of oral hydromorphone daily or at least 25 mg oral oxymorphone daily, or an equianalgesic dose of another opioid medication daily for a week or longer. Patients must remain on around-the-clock opioids when taking ABSTRAL.
ABSTRAL is contraindicated for patients who are not already tolerant to opioids because life-threatening respiratory depression and death could result at any dose in patients not on a chronic regimen of opioids. For this reason, ABSTRAL is contraindicated in the management of acute or postoperative pain, including headache/migraine, dental pain, or use in the emergency room.
ABSTRAL is intended to be prescribed only by healthcare professionals who are knowledgeable of, and skilled in, the use of Schedule II opioids to treat cancer pain.
Limitations of Use:
As a part of the TIRF REMS Access program, ABSTRAL may be dispensed only to outpatients enrolled in the program [see Warnings and Precautions (5.10)]. For inpatient administration of ABSTRAL (e.g., hospitals, hospices, and long-term care facilities that prescribe for inpatient use), patient and prescriber enrollment is not required.
Healthcare professionals who prescribe ABSTRAL on an outpatient basis must enroll in the TIRF REMS
Access program and comply with the requirements of the REMS to ensure safe use of ABSTRAL [See Warnings and Precautions (5.10)].
As with all opioids, the safety of patients using such products is dependent on health care professionals prescribing them in strict conformity with their approved labeling with respect to patient selection, dosing, and proper conditions for use.
The objective of dose titration is to identify an effective and tolerable maintenance dose for ongoing management of breakthrough cancer pain episodes. The effective and tolerable dose of ABSTRAL will be determined by dose titration in individual patients.
Carefully supervise patients until a dose that provides adequate analgesia with tolerable side effects is reached for breakthrough pain control.
Starting Dose: Individually titrate ABSTRAL to a dose that provides adequate analgesia with tolerable side effects. Begin titration of all patients with an initial dose of ABSTRAL of 100 mcg. Due to differences in the pharmacokinetic properties and individual variability, even patients switching from other fentanyl containing products to ABSTRAL must start with the 100 mcg dose. However, for patients converting from Actiq, see Table 1: Initial Dosing Recommendations for Patients on ACTIQ. ABSTRAL is not equivalent on a mcg per mcg basis with all other fentanyl products, therefore, do not switch patients on a mcg per mcg basis from any other fentanyl product. ABSTRAL is NOT a generic version of any other fentanyl product.
Start all patients with a single 100 mcg tablet.
Titration Steps: If adequate analgesia was not obtained with the first 100 mcg dose, continue dose escalation in a stepwise manner over consecutive breakthrough episodes until adequate analgesia with tolerable side effects is achieved. Increase the dose by 100 mcg multiples up to 400 mcg as needed. If adequate analgesia is not obtained with a 400 mcg dose, the next titration step is 600 mcg. If adequate analgesia is not obtained with a 600 mcg dose, the next titration step is 800 mcg. During titration, patients can be instructed to use multiples of 100 mcg tablets and/or 200 mcg tablets for any single dose. Instruct patients not to use more than 4 tablets at one time. If adequate analgesia is not obtained 30 minutes after the use of ABSTRAL, the patient may repeat the same dose of ABSTRAL. No more than two doses of ABSTRAL may be used to treat an episode of breakthrough pain. Rescue medication as directed by the health care provider can be used if adequate analgesia is not achieved after use of ABSTRAL.
The efficacy and safety of doses higher than 800 mcg have not been evaluated in clinical studies in patients.
In order to minimize the risk of ABSTRAL-related adverse reactions and to identify the appropriate dose, it is imperative that patients be supervised closely by health professionals during the titration process.
The initial dose of Abstral is always 100 mcg with the only exception being patients already using Actiq.
| Current ACTIQ Dose (mcg) Initial Abstral Dose (mcg) | |
| 200 | 100 mcg |
| 400 | 200 mcg |
| 600 | 200 mcg |
| 800 | 200 mcg |
| 1200 | 200 mcg |
| 1600 | 400 mcg |
Once an appropriate dose for pain management has been established, instruct patients to use only one ABSTRAL tablet of the appropriate strength per dose. Maintain patients on this dose.
If adequate analgesia is not obtained after use of ABSTRAL, the patient may use a second ABSTRAL dose (after 30 minutes) as directed by their health care provider. No more than two doses of ABSTRAL may be used to treat an episode of breakthrough pain.
Patients must wait at least 2 hours before treating another episode of breakthrough pain with ABSTRAL.
If the response (analgesia or adverse reactions) to the titrated ABSTRAL dose markedly changes, an adjustment of dose may be necessary to ensure that an appropriate dose is maintained.
If more than four episodes of breakthrough pain are experienced per day, re-evaluate the dose of the longacting opioid used for persistent underlying cancer pain. If the long-acting opioid or dose of long-acting opioid is changed, re-evaluate and re-titrate the ABSTRAL dose as necessary to ensure the patient is on an appropriate dose.
Limit the use of ABSTRAL to treat four or fewer episodes of breakthrough pain per day.
It is imperative that any dose re-titration is monitored carefully by a healthcare professional.
Place ABSTRAL tablets on the floor of the mouth directly under the tongue immediately after removal from the blister unit. Do not chew, suck, or swallow ABSTRAL tablets. Allow ABSTRAL tablets to completely dissolve in the sublingual cavity. Advise patients not to eat or drink anything until the tablet is completely dissolved.
In patients who have a dry mouth, water may be used to moisten the buccal mucosa before taking ABSTRAL.
For patients no longer requiring opioid therapy, consider discontinuing ABSTRAL along with a gradual downward titration of other opioids to minimize possible withdrawal effects.
In patients who continue to take their chronic opioid therapy for persistent pain but no longer require treatment for breakthrough pain, ABSTRAL therapy can usually be discontinued immediately.
ABSTRAL is formulated as a sublingual tablet and is available in six strengths, distinguishable by the shape of the tablet and by de- bossing on the tablet surface. All tablets are white:
100 microgram tablet is a round tablet marked with the number "1"
200 microgram tablet is an oval-shaped tablet marked with the number "2"
300 microgram tablet is a triangle-shaped tablet marked with the number "3"
400 microgram tablet is a diamond-shaped tablet marked with the number "4"
600 microgram tablet is a "D"-shaped tablet marked with the number "6"
800 microgram tablet is a capsule-shaped tablet marked with the number "8"
[see How Supplied/Storage and Handling (16.4)].
ABSTRAL is contraindicated in the management of pain in opioid non-tolerant patients, because lifethreatening hypoventilation could occur at any dose in patients not already taking around-the-clock opioid therapy. Patients considered opioid tolerant are those who are taking at least 60 mg oral morphine/day, or at least 25 mcg transdermal fentanyl/hour, 30 mg oral oxycodone/day, 8 mg oral hydromorphone/day, 25 mg oral oxymorphone/day, or an equianalgesic dose of another opioid for a week or longer.
ABSTRAL is contraindicated in the management of acute or postoperative pain, including headache/migraine, dental pain, or use in the emergency room.
ABSTRAL is contraindicated in patients with known intolerance or hypersensitivity to any of its components or the drug fentanyl. Anaphylaxis and hypersensitivity have been reported in association with the use of other oral transmucosal fentanyl products.
See Boxed Warning- WARNINGS: IMPORTANCE OF PROPER PATIENT SELECTION and POTENTIAL FOR ABUSE
Serious or fatal respiratory depression can occur even at recommended doses in patients using ABSTRAL. Respiratory depression is more likely to occur in patients with underlying respiratory disorders and elderly or debilitated patients, usually following large initial doses, including ABSTRAL, in opioid non-tolerant patients, or when opioids are given in conjunction with other drugs that depress respiration.
Respiratory depression from opioids is manifested by a reduced urge to breathe and a decreased rate of respiration, often associated with the "sighing" pattern of breathing (deep breaths separated by abnormally long pauses). Carbon dioxide retention from opioid- induced respiratory depression can exacerbate the sedating effects of opioids. This makes overdoses involving drugs with sedative properties and opioids especially dangerous.
ABSTRAL is NOT equivalent to all other fentanyl products used to treat breakthrough pain on a mcg per mcg basis. There are differences in the pharmacokinetics of ABSTRAL relative to other fentanyl products which could potentially result in clinically important differences in the amount of fentanyl absorbed and could result in a fatal overdose.
When prescribing ABSTRAL to a patient, DO NOT convert on a mcg to mcg basis from other fentanyl products. Directions for safely converting patients to ABSTRAL from other fentanyl products are not currently available except for Actiq [see Conversion from Actiq (2.2) ]. This includes oral, transdermal, or parenteral formulations of fentanyl. Therefore, for opioid-tolerant patients starting treatment for breakthrough pain, the initial dose of ABSTRAL is 100 mcg. Individually titrate each patient's dose to provide adequate analgesia while minimizing side effects. [See Dosage and Administration (2.1)]
When dispensing ABSTRAL to a patient, DO NOT substitute it for any other fentanyl product prescription.
Patients and their caregivers must be instructed that ABSTRAL contains a medicine in an amount which can be fatal to a child. Even though ABSTRAL is provided in child-resistant packaging, patients and their caregivers must be instructed to keep tablets out of the reach of children. [see How Supplied/Storage and Handling (16.1, 16.2), and Patient Counseling Information (17.1, 17.2)].
Taking ABSTRAL could be fatal in individuals for whom it is not prescribed and for those who are not opioid-tolerant.
Physicians and dispensing pharmacists must specifically question patients or caregivers about the presence of children in the home (on a full time or visiting basis) and counsel them regarding the dangers to children from inadvertent exposure.
The concomitant use of ABSTRAL with other CNS depressants, including other opioids, sedatives or hypnotics, general anesthetics, phenothiazines, tranquilizers, skeletal muscle relaxants, sedating antihistamines, and alcoholic beverages may produce increased depressant effects (e.g., hypoventilation, hypotension, and profound sedation). Concomitant use with potent inhibitors of cytochrome P450 3A4 isoform (e.g., erythromycin, ketoconazole, and certain protease inhibitors) may increase fentanyl levels, resulting in increased depressant effects [see Drug Interactions (7)].
Patients on concomitant CNS depressants must be monitored for a change in opioid effects and the dose of ABSTRAL adjusted, if warranted.
Opioid analgesics impair the mental and/or physical ability required for the performance of potentially dangerous tasks (e.g., driving a car or operating machinery). Warn patients taking ABSTRAL of these dangers and counsel them accordingly.
Because potent opioids can cause hypoventilation, titrate ABSTRAL with caution in patients with chronic obstructive pulmonary disease or pre-existing medical conditions predisposing them to hypoventilation. In such patients, even normal therapeutic doses of ABSTRAL may further decrease respiratory drive to the point of respiratory failure.
Administer ABSTRAL with extreme caution in patients who may be particularly susceptible to the intracranial effects of CO2 retention such as those with evidence of increased intracranial pressure or impaired consciousness. Opioids may obscure the clinical course of a patient with a head injury; use only if clinically warranted.
Intravenous administration of fentanyl may produce bradycardia. Therefore, use ABSTRAL with caution in patients with bradyarrhythmias.
ABSTRAL is not recommended for use in patients who have received MAO inhibitors within the past 14 days.
Severe and unpredictable potentiation by MAO inhibitors has been reported with opioid analgesics.
Because of the risk for misuse, abuse, addiction, and overdose [see Drug Abuse and Dependence (9)], ABSTRAL is available only through a restricted program called the TIRF REMS Access program. Under the TIRF REMS Access program, outpatients, healthcare professionals who prescribe to outpatients, pharmacies, and distributors must enroll in the program. For inpatient administration (e.g., hospitals, hospices, and longterm care facilities that prescribe for inpatient use) of ABSTRAL, patient and prescriber enrollment is not required.
Required components of the TIRF REMS Access program are:
Further information, including a list of qualified pharmacies/distributors, is available at www.TIRFREMSAccess.com or by calling 1-866-822-1483.
Because clinical trials are conducted under widely varying conditions, adverse event rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The safety of ABSTRAL has been evaluated in 311 opioid-tolerant cancer patients with breakthrough pain. Two hundred and seventy (270) of these patients were treated in multiple-dose studies. The duration of therapy for patients in multiple-dose studies ranged from 1-405 days with an average duration of 131 days and with 44 patients treated for at least 12 months.
The most commonly observed adverse reactions with ABSTRAL include typical opioid adverse reactions, such as nausea, constipation, somnolence and headache. Expect opioid side effects and manage them accordingly.
The clinical trials of ABSTRAL were designed to evaluate safety and efficacy in treating patients with cancer and breakthrough pain; all patients were taking concomitant opioids, such as sustained-release morphine, sustained-release oxycodone or transdermal fentanyl, for their persistent pain.
The adverse reaction data presented in Table 2 reflect the actual percentage of patients experiencing reactions among patients who received ABSTRAL for breakthrough pain along with concomitant opioid use for persistent pain. There has been no attempt to correct for concomitant use of other opioids, duration of ABSTRAL therapy or cancer-related symptoms.
Table 2 lists adverse reactions with an overall frequency of 5% or greater within the total population that occurred during titration by maximum dose received. The ability to assign ABSTRAL a dose-response relationship to these adverse reactions is limited by the titration schemes used in these studies.
| System Organ Class Preferred term N (%) | 100 mcg (n=22) | 200 mcg (n=23) | 300 mcg (n=55) | 400 mcg (n=38) | 600 mcg (n=52) | 800 mcg (n=80) | Total (n=270) |
| Gastrointestinal disorders | |||||||
| Nausea | 1 (4.5) | 4 (17.4) | 5 (9.1) | 1 (2.6) | 2 (3.8) | 2 (2.5) | 15 (5.6) |
| Nervous system disorders | |||||||
| Somnolence | 0 | 2 (8.7) | 4 (7.3) | 2 (5.3) | 2 (3.8) | 2 (2.5) | 12 (4.4) |
| Dizziness | 0 | 0 | 3 (5.5) | 2 (5.3) | 0 | 1 (1.3) | 6 (2.2) |
| Headache | 0 | 0 | 0 | 1 (2.6) | 3 (5.8) | 1 (1.3) | 5 (1.9) |
Table 3 lists, by successful dose, adverse reactions with an overall frequency of ≥ 5% within the total population that occurred after a successful dose had been determined.
| System Organ Class Preferred term N (%) | 100 mcg (n=7) | 200 mcg (n=12) | 300 mcg (n=22) | 400 mcg (n=20) | 600 mcg (n=35) | 800 mcg (n=72) | Total (n=168) |
| Gastrointestinal disorders | |||||||
| Nausea | 1 (14.3) | 0 | 2 (9.1) | 0 | 1 (2.9) | 6 (8.3) | 10 (6.0) |
| Stomatitis | 0 | 1 (8.3) | 1 (4.5) | 0 | 0 | 1 (1.4) | 3 (1.8) |
| Constipation | 0 | 0 | 1 (4.5) | 2 (10.0) | 1 (2.9) | 4 (5.6) | 8 (4.8) |
| Dry mouth | 0 | 0 | 0 | 1 (5.0) | 2 (5.7) | 0 | 3 (1.8) |
| Nervous system disorders | |||||||
| Headache | 0 | 0 | 0 | 2 (10.0) | 1 (2.9) | 2 (2.8) | 5 (3.0) |
| Dysgeusia | 1 (14.3) | 0 | 0 | 0 | 0 | 1 (1.4) | 2 (1.2) |
| General disorders and administration site conditions | |||||||
| Fatigue | 0 | 0 | 0 | 1 (5.0) | 2 (5.7) | 0 | 3 (1.8) |
| Injury, poisoning and procedural complications | |||||||
| Accidental overdose | 1 (14.3) | 0 | 0 | 0 | 0 | 0 | 1 (0.6) |
| Respiratory, thoracic and mediastinal disorders | |||||||
| Dyspnoea | 0 | 1 (8.3) | 0 | 0 | 0 | 0 | 1 (0.6) |
| Skin and subcutaneous disorders | |||||||
| Hyperhidrosis | 1 (14.3) | 0 | 0 | 0 | 0 | 1 (1.4) | 2 (1.2) |
The frequencies listed below represent adverse reactions that occurred in ≥ 1% of patients from two clinical trials who experienced that reaction while receiving ABSTRAL. Reactions are classified by system organ class.
Adverse Reactions (≥ 1%)
Cardiac disorders: bradycardia, tachycardia.
Eye disorders: vision blurred.
Gastrointestinal disorders: abdominal pain, abdominal pain upper, aphthous stomatitis, constipation, dry mouth, dyspepsia, gingival ulceration, impaired gastric emptying, lip ulceration, mouth ulceration, nausea, stomach discomfort, stomatitis, tongue disorder, vomiting.
General disorders and administration site conditions: asthenia, drug withdrawal syndrome, fatigue, malaise.
Immune system disorders: drug hypersensitivity.
Injury, poisoning and procedural complications: accidental overdose.
Metabolism and nutrition disorders: anorexia, decreased appetite.
Nervous system disorders: amnesia, disturbance in attention, dizziness, dysgeusia, headache, hypoesthesia, lethargy, parosmia, somnolence, tremor.
Psychiatric disorders: affect lability, anxiety, confusional state, depression, disorientation, dysphoria, euphoric mood, insomnia, mental status changes, paranoia, sleep disorder.
Reproductive system and breast disorders: erectile dysfunction.
Respiratory, thoracic and mediastinal disorder: dyspnea, oropharyngeal pain, throat tightness.
Skin and subcutaneous disorders: hyperhidrosis, night sweats, pruritus, rash, skin lesion.
Vascular disorders: hypotension.
Fentanyl is metabolized mainly via the human cytochrome P450 3A4 isoenzyme system (CYP3A4); therefore potential interactions may occur when ABSTRAL is given concurrently with agents that affect CYP3A4 activity.
The concomitant use of ABSTRAL with CYP3A4 inhibitors (e.g., indinavir, nelfinavir, ritonavir, clarithromycin, itraconazole, ketoconazole, nefazodone, saquinavir, telithromycin, aprepitant, diltiazem, erythromycin, fluconazole, grapefruit juice, verapamil, or cimetidine) may result in a potentially dangerous increase in fentanyl plasma concentrations, which could increase or prolong adverse drug effects and may cause potentially fatal respiratory depression. Patients receiving ABSTRAL who begin therapy with, or increase the dose of, CYP3A4 inhibitors need to be carefully monitored for signs of opioid toxicity over an extended period of time. Increase dosage conservatively.
The concomitant use of ABSTRAL with CYP3A4 inducers (e.g., barbiturates, carbamazepine, efavirenz, glucocorticoids, modafinil, nevirapine, oxcarbazepine, phenobarbital, phenytoin, pioglitazone, rifabutin, rifampin, St. John's wort, or troglitazone) may result in a decrease in fentanyl plasma concentrations, which could decrease the efficacy of ABSTRAL.
Patients receiving ABSTRAL who stop therapy with, or decrease the dose of, CYP3A4 inducers need to be monitored for signs of increased ABSTRAL activity and the dose of ABSTRAL must be adjusted accordingly.
There are no adequate and well-controlled studies in pregnant women.
Use ABSTRAL during pregnancy only if the potential benefit justifies the potential risk to the fetus. No epidemiological studies of congenital anomalies in infants born to women treated with fentanyl during pregnancy have been reported.
Chronic maternal treatment with fentanyl during pregnancy has been associated with transient respiratory depression, behavioral changes, or seizures in newborn infants characteristic of neonatal abstinence syndrome.
In women treated acutely with intravenous or epidural fentanyl during labor, symptoms of neonatal respiratory or neurological depression were no more frequent than would be expected in infants of untreated mothers.
Transient neonatal muscular rigidity has been observed in infants whose mothers were treated with intravenous fentanyl.
Fentanyl is embryocidal in rats as evidenced by increased resorptions in pregnant rats at doses of 30 mcg/kg intravenously or 160 mcg/kg subcutaneously. Conversion to human equivalent doses indicates this is within the range of the human recommended dosing for ABSTRAL.
Fentanyl citrate was not teratogenic when administered to pregnant animals. Published studies demonstrated that administration of fentanyl (10, 100, or 500 mcg/kg/day) to pregnant rats from day 7 to 21, of their 21 day gestation, via implanted microosmotic minipumps, was not teratogenic (the high dose was approximately 6times the human dose of 800 mcg per pain episode on a mcg/m2 basis). Intravenous administration of fentanyl (10 mcg/kg or 30 mcg/kg) to pregnant female rats from gestation day 6 to 18, was embryo- or feto-toxic, and caused a slightly increased mean delivery time in the 30 mcg/kg/day group, but was not teratogenic.
Fentanyl readily crosses the placenta. Therefore do not use ABSTRAL during labor and delivery (including caesarean section) since it may cause respiratory depression in the fetus or in the newborn infant.
Fentanyl is excreted in human milk; therefore, do not use ABSTRAL in women who are nursing because of the possibility of sedation and/or respiratory depression in their infants. Symptoms of opioid withdrawal may occur in infants at the cessation of nursing by women using ABSTRAL.
The safety and efficacy of ABSTRAL have not been established in patients below 18 years of age.
Of the 270 opioid tolerant patients with breakthrough cancer pain in the Phase 3 clinical studies of Abstral, 58 (21%) were 65 years of age and older. There was no difference in the median titrated dose in patients aged 65 years and older compared to those <65 years. No clinically meaningful difference was noted in the safety profile of the group 65 years of age and older as compared to younger patients in ABSTRAL clinical trials.
Elderly patients have been shown to be more sensitive to the effects of fentanyl when administered intravenously, compared with the younger adult population. Therefore, exercise caution when individually titrating ABSTRAL in elderly patients to provide adequate efficacy while minimizing risk.
Insufficient information exists to make recommendations regarding the use of ABSTRAL in patients with impaired renal or hepatic function. Fentanyl is metabolized primarily via human cytochrome P450 3A4 isoenzyme system and the inactive metabolite is mostly eliminated in urine. If the drug is used in these patients, use the drug with caution because of the reduced hepatic metabolism and renal excretion capacity in such patients.
Both male and female opioid-tolerant cancer patients were studied for the treatment of breakthrough cancer pain. No clinically relevant gender differences were noted either in efficacy or in observed adverse reactions.
ABSTRAL contains fentanyl, a Schedule II substance. Schedule II opioid substances such as fentanyl, hydromorphone, methadone, morphine, oxycodone, and oxymorphone have a high potential for abuse and addiction. ABSTRAL is also subject to misuse and criminal diversion.
Manage the handling of ABSTRAL to minimize the risk of misuse, including the restriction of access and accounting procedures as appropriate to the clinical setting and as required by law [see How Supplied/Storage and Handling (16.2, 16.3)].
Concerns about abuse, addiction, and diversion must not prevent the proper management of pain. However, all patients treated with opioids require careful monitoring for signs of abuse and addiction, because use of opioid analgesic products carries the risk of addiction even under appropriate medical use.
Addiction is a primary, chronic, neurobiologic disease, with genetic, psychosocial, and environmental factors influencing its development and manifestations. It is characterized by behaviors that include one or more of the following: impaired control over drug use, compulsive use, continued use despite harm, and craving. Drug addiction is a treatable disease, utilizing a multidisciplinary approach, but relapse is common. "Drug-seeking" behavior is very common in addicts and drug abusers.
Abuse and addiction are separate and distinct from physical dependence and tolerance. Be aware that addiction may not be accompanied by concurrent tolerance and symptoms of physical dependence in all addicts. In addition, abuse of opioids can occur in the absence of addiction and is characterized by misuse for non-medical purposes, often in combination with other psychoactive substances. Since ABSTRAL may be diverted for nonmedical use, careful record keeping of prescribing information, including quantity, frequency, and renewal requests is strongly advised.
Proper patient assessment, safe prescribing practices, periodic re-evaluation of therapy, and proper dispensing and storage are appropriate measures that help to limit abuse of opioid drugs.
Contact your State Professional Licensing Board, or State Controlled Substances Authority for information on how to prevent and detect abuse or diversion of this product.
Physical dependence is not ordinarily a concern in the treatment of patients with chronic cancer pain, and fear of tolerance and physical dependence must not deter using opiate doses that adequately relieve the pain. Guide the administration of Abstral by the response of the patient.
Opioid analgesics may cause physical dependence that can result in withdrawal symptoms in patients who abruptly discontinue the drug. Withdrawal also may be precipitated through the administration of drugs with opioid antagonist activity (e.g., naloxone, nalmefene) or mixed agonist/antagonist analgesics (pentazocine, butorphanol, buprenorphine, nalbuphine).
Physical dependence usually does not occur to a clinically significant degree until after several weeks of continued opioid usage. Tolerance, in which increasingly larger doses are required in order to produce the same degree of analgesia, is initially manifested by a shortened duration of analgesic effect, and subsequently, by decreases in the intensity of analgesia.
The manifestations of ABSTRAL overdosage are expected to be similar in nature to intravenous fentanyl and other opioids, and are an extension of its pharmacological actions with the most serious significant effect being hypoventilation [see Clinical Pharmacology (12.2)].
Immediate management of opioid overdose includes removal of the ABSTRAL tablet, if still in the mouth, ensuring a patent airway, physical and verbal stimulation of the patient, and assessment of level of consciousness, ventilatory and circulatory status.
Provide ventilatory support, obtain intravenous access, and administer naloxone or other opioid antagonists as clinically indicated. The duration of respiratory depression following overdose may be longer than the effects of the opioid antagonist's action (e.g., the half-life of naloxone ranges from 30 to 81 minutes) and repeated administration may be necessary. Consult the package insert of the individual opioid antagonist for details.
Provide ventilatory support and obtain intravenous access as clinically indicated. Judicious use of naloxone or another opioid antagonist may be warranted in some instances, but at the risk of precipitating an acute withdrawal syndrome.
Management of severe ABSTRAL overdose includes: securing a patent airway, assisting or controlling ventilation and establishing intravenous access. In the presence of hypoventilation or apnea, assist or control ventilation, and administer oxygen as indicated.
Carefully observe and appropriately manage patients with overdose until their clinical condition is well controlled.
Although muscle rigidity interfering with respiration has not been seen following the use of ABSTRAL, this is possible with fentanyl and other opioids. If it occurs, manage it by using assisted or controlled ventilation, by an opioid antagonist, and as a final alternative, by a neuromuscular blocking agent.
ABSTRAL (fentanyl) sublingual tablet is a solid formulation of fentanyl citrate, a potent opioid analgesic intended for oral sublingual administration. ABSTRAL is formulated as a white tablet available in six strengths, distinguishable by the shape of the tablet and by de-bossing on the tablet surface.
Active Ingredient: Fentanyl citrate, USP is N-(1-Phenethyl-4-piperidyl) propionanilide citrate (1:1). Fentanyl is a highly lipophilic compound (octanol-water partition coefficient at pH 7.4 is 816:1) that is freely soluble in organic solvents and sparingly soluble in water (1:40). The molecular weight of the free base is 336.5 (the citrate salt is 528.6). The pKa of the tertiary nitrogens are 7.3 and 8.4. The compound has the following structural formula:
All tablet strengths are expressed as the amount of fentanyl free base, e.g., the 100 mcg strength tablet contains 100 mcg of fentanyl free base.
Inactive Ingredients: Croscarmellose sodium, magnesium stearate, mannitol, and silicified microcrystalline cellulose.
Fentanyl is a pure opioid agonist whose principal therapeutic action is analgesia. Other members of the class known as opioid agonists include substances such as morphine, oxycodone, hydromorphone, codeine, and hydrocodone.
Pharmacological effects of opioid agonists include anxiolysis, euphoria, feelings of relaxation, respiratory depression, constipation, miosis, cough suppression, and analgesia. Like all pure opioid agonist analgesics, with increasing doses there is increasing analgesia, unlike with mixed agonist/antagonists or non-opioid analgesics, where there is a limit to the analgesic effect with increasing doses. With pure opioid agonist analgesics, there is no defined maximum dose; the ceiling to analgesic effectiveness is imposed only by side effects, the more serious of which may include somnolence and respiratory depression. Analgesia
In general, the effective concentration and the concentration at which toxicity occurs increase with increasing tolerance with any and all opioids. The rate of development of tolerance varies widely among individuals. As a result, individually titrate the dose of ABSTRAL to achieve the desired effect [see Dosage and Administration (2)].
Central Nervous System
The precise mechanism of the analgesic action is unknown although fentanyl is known to be a μ-opioid receptor agonist. Specific CNS opioid receptors for endogenous compounds with opioid-like activity have been identified throughout the brain and spinal cord and play a role in the analgesic effects of this drug.
Fentanyl produces respiratory depression by direct action on brain stem respiratory centers. The respiratory depression involves both a reduction in the responsiveness of the brain stem to increases in carbon dioxide and to electrical stimulation.
Fentanyl causes miosis even in total darkness. Pinpoint pupils are a sign of opioid overdose but are not pathognomonic (e.g., pontine lesions of hemorrhagic or ischemic origin may produce similar findings).
Gastrointestinal System
Fentanyl causes a reduction in motility associated with an increase in smooth muscle tone in the antrum of the stomach and in the duodenum. Digestion of food is delayed in the small intestine and propulsive contractions are decreased. Propulsive peristaltic waves in the colon are decreased, while tone may be increased to the point of spasm resulting in constipation. Other opioid induced-effects may include a reduction in gastric, biliary and pancreatic secretions, spasm of the sphincter of Oddi, and transient elevations in serum amylase.
Cardiovascular System
Fentanyl may produce release of histamine with or without associated peripheral vasodilation. Manifestations of histamine release and/or peripheral vasodilation may include pruritus, flushing, red eyes, sweating, and/or orthostatic hypotension.
Endocrine System
Opioid agonists have been shown to have a variety of effects on the secretion of hormones. Opioids inhibit the secretion of ACTH, cortisol, and luteinizing hormone (LH) in humans. They also stimulate prolactin secretion, growth hormone (GH) secretion, and pancreatic secretion of insulin and glucagon in humans and other species (e.g., rats and dogs). Thyroid stimulating hormone (TSH) has been shown to be both inhibited and stimulated by opioids.
Respiratory System
All opioid mu-receptor agonists, including fentanyl, produce dose-dependent respiratory depression. The risk of respiratory depression is less in patients receiving chronic opioid therapy who develop tolerance to these effects. Peak respiratory depressive effects may be seen as early as 15 to 30 minutes from the start of oral transmucosal fentanyl citrate administration and may persist for several hours.
Serious or fatal respiratory depression can occur even at recommended doses. Fentanyl depresses the cough reflex as a result of its CNS activity. Although not observed with oral transmucosal fentanyl products in clinical trials, fentanyl given rapidly by intravenous injection in large doses may cause rigidity in the muscles of respiration resulting in respiratory difficulties. Therefore, be aware of this potential complication [see Boxed Warning - Warnings: Importance Of Proper Patient Selection and Potential for Abuse, Contraindications (4), Warnings And Precautions (5.1), Adverse Reactions (6), and Overdosage (10)].
Absorption
Fentanyl is a highly lipophilic drug. Orally administered fentanyl undergoes pronounced hepatic and intestinal first pass effects. Absorption of fentanyl from ABSTRAL sublingual tablets is mainly through the oral mucosa.
The bioavailability of ABSTRAL sublingual tablets has been calculated to be 54%.
Dose proportionality across the 100 mcg to 800 mcg ABSTRAL dose range has been demonstrated (Table4). Mean plasma fentanyl levels following single doses of ABSTRAL are shown in Figure 1. The median time to maximum plasma concentration (Tmax) across these four doses of ABSTRAL varied from 30 to 60 minutes (range of 15 - 240 minutes).
Figure 1: Mean (+/- SD) Plasma Fentanyl Concentration versus Time after Administration of Single Doses of 100 mcg, 200 mcg, 400 mcg and 800 mcg ABSTRAL to Healthy Subjects
Pharmacokinetic parameters are presented in Table 4.
| |||||
| Parameter | Unit | Abstral dose | |||
| 100 mcg | 200 mcg | 400 mcg | 800 mcg | ||
| Cmax | (ng/mL) | 0.187 (33) | 0.302 (31) | 0.765 (38) | 1.42 (33) |
| Tmaxa | (min) | 30 [19-120] | 52 [16-240] | 60 [30-120] | 30 [15-60] |
| AUC0-inf | (ng.h/mL) | 0.974 (34) | 1.92 (27) | 5.49 (35) | 8.95 (33) |
| T1/2 | (h) | 5.02 (51) | 6.67 (30) | 13.5 (37) | 10.1 (34) |
In another study, dose proportionality between 800 mcg and 1600 mcg in Cmax and AUC has also been demonstrated.
Pharmacokinetic studies have shown that multiple tablets are bioequivalent to single tablets of the equivalent dose.
Distribution
Fentanyl is highly lipophilic. Animal data showed that following absorption, fentanyl is rapidly distributed to the brain, heart, lungs, kidneys and spleen followed by a slower redistribution to muscles and fat. The plasma protein binding of fentanyl is 80-85%. The main binding protein is alpha-1-acid glycoprotein, but both albumin and lipoproteins contribute to some extent. The free fraction of fentanyl increases with acidosis. The mean volume of distribution at steady state (Vss) was 4 L/kg. Metabolism
Fentanyl is metabolized in the liver and in the intestinal mucosa to norfentanyl by cytochrome P450 3A4 isoform. Norfentanyl was not found to be pharmacologically active in animal studies [see Drug Interactions (7)].
Elimination
Fentanyl is more than 90% eliminated by biotransformation to N-dealkylated and hydroxylated inactive metabolites. Less than 7% of the dose is excreted unchanged in the urine, and only about 1% is excreted unchanged in the feces. The metabolites are mainly excreted in the urine, while fecal excretion is less important. The total plasma clearance of fentanyl was 0.5 L/hr/kg (range 0.3 - 0.7 L/ hr/kg).
Long-term studies in animals have not been performed to evaluate the carcinogenic potential of fentanyl.
Fentanyl citrate was not mutagenic in the in vitro Ames reverse mutation assay in S. typhimurium or E. coli, or the mouse lymphoma mutagenesis assay, and was not clastogenic in the in vivo mouse micronucleus assay.
Fentanyl has been shown to impair fertility in rats at doses of 30 mcg/kg intravenously and 160 mcg/kg subcutaneously. Conversion to the human equivalent doses indicates that this is within the range of the human recommended dosing for ABSTRAL.
The efficacy of ABSTRAL was investigated in a clinical trial in opioid tolerant adult patients experiencing breakthrough cancer pain. Breakthrough cancer pain was defined as a transient flare of moderate-to-severe pain occurring in patients with cancer experiencing persistent cancer pain otherwise controlled with maintenance doses of opioid medications including at least 60 mg morphine/day, 50 mcg transdermal fentanyl/hour, or an equianalgesic dose of another opioid for 1 week or longer. All patients were on stable doses of either long-acting oral opioids or transdermal fentanyl for their persistent cancer pain.
A double-blind, placebo-controlled, crossover study was performed in patients with cancer to evaluate the effectiveness of ABSTRAL for the treatment of breakthrough cancer pain. Open-label titration identified a dose of ABSTRAL in which a patient obtained adequate analgesia with tolerable side effects, within the range of 100 mcg to 800 mcg. In the double-blind efficacy study, patients who identified a successful dose were randomized to a sequence of 10 treatments; seven with ABSTRAL and three with placebo.
Of the 131 patients who entered the titration phase of the study, 78 (60%) achieved a successful dose during the titration phase. Sixty- six patients entered the double-blind phase and 60 completed the study. The dose of ABSTRAL was determined by titration starting at 100 mcg. The final titrated dose of ABSTRAL for breakthrough cancer pain was not predicted from the daily maintenance dose of opioid used to manage the persistent cancer pain. In a second open-label safety study using an identical titration regimen, 96 of 139 patients (69%) who entered the study titrated to a dose in which the patient obtained adequate analgesia with tolerable side effects during the titration phase. Table 5 presents the final titrated dose for both the doubleblind efficacy and open-label safety studies.
| ABSTRAL Dose | N=174 n (%) |
| 100 mcg | 11 (6) |
| 200 mcg | 15 (9) |
| 300 mcg | 35 (20) |
| 400 mcg | 25 (14) |
| 600 mcg | 40 (23) |
| 800 mcg | 48 (28) |
The primary outcome measure, the mean sum of pain intensity difference at 30 minutes (SPID30) for ABSTRAL-treated episodes was statistically significantly higher than for placebo-treated episodes.
Figure 2: Mean Pain Intensity Difference (±SE) for ABSTRAL Compared to Placebo
ABSTRAL is supplied in individually sealed child-resistant blister packages contained in a cardboard outer carton, in pack sizes of 12 (100 mcg, 200 mcg, 300 mcg and 400 mcg strengths) or 32 (all strengths) tablets. The packaging is color-coded for each ABSTRAL tablet strength.
The amount of fentanyl contained in ABSTRAL can be fatal to a child, individual for whom it is not prescribed or non-opioid tolerant adult. Patients and their caregivers must be instructed to keep ABSTRAL out of the reach of children [see Boxed Warning - Warnings: Potential For Abuse and Importance Of Proper Patient Selection and Warnings And Precautions (5), and Patient Counseling Information (17.1)].
Store at 20-25°C (68-77°F); excursions permitted between 15-30°C (59-86°F) [see USP Controlled Room Temperature]. Protect from moisture.
Patients and their household members must be advised to dispose of any tablets remaining from a prescription as soon as they are no longer needed. Instructions are included in Patient Counseling Information (17.2) and in the Medication Guide.
To dispose of any unused ABSTRAL tablets, remove them from the blister cards and flush down the toilet. Do not dispose of the ABSTRAL blister cards or cartons down the toilet.
If additional assistance is required, call Galena Biopharma, Inc. at 1-888-227-8725.
ABSTRAL is supplied in six dosage strengths. Tablets are supplied in child-resistant, protective blister cards with peelable foil. Each blister card contains 4 tablets, in pack sizes of 12 (100 mcg, 200 mcg, 300 mcg and 400 mcg strengths) or 32 (all strengths) tablets. Each tablet is white in color, with the strength distinguishable by the shape of the dosage unit and by de-bossing on the tablet surface:
| Dosage Strength (fentanyl base) | Tablet Shape | Tablet Markings | Carton/Blister Package Color | Pack size | NDC Number |
| 100 mcg | Round | "1" | Light blue | 12 | 57881-331-12 |
| 32 | 57881-331-32 | ||||
| 200 mcg | Oval | "2" | Dark orange | 12 | 57881-332-12 |
| 32 | 57881-332-32 | ||||
| 300 mcg | Triangle | "3" | Brown | 12 | 57881-333-12 |
| 32 | 57881-333-32 | ||||
| 400 mcg | Diamond | "4" | Violet | 12 | 57881-334-12 |
| 32 | 57881-334-32 | ||||
| 600 mcg | "D" | "6" | Turquoise | 32 | 57881-336-32 |
| 800 mcg | Capsule | "8" | Indigo | 32 | 57881-338-32 |
Note: Colors and shapes are a secondary aid in product identification. Please be sure to confirm the printed dosage before dispensing.
See FDA-approved patient labeling (Medication Guide)
Patient/Caregiver Instructions
Disposal of Unopened ABSTRAL Blister Packages When No Longer Needed
Medication Guide
ABSTRAL® (AB-stral) CII
(fentanyl)
Sublingual tablets
100 mcg, 200 mcg, 300 mcg, 400 mcg, 600 mcg, 800 mcg
| IMPORTANT: Do not use ABSTRAL unless you are regularly using another opioid pain medicine around-the-clock for your cancer pain and your body is used to these medicines (this means that you are opioid tolerant). Keep ABSTRAL in a safe place away from children. Get emergency medical help right away if:
|
Read this Medication Guide completely before you start taking ABSTRAL, and each time you get a new prescription. There may be new information. This Medication Guide does not take the place of talking to your healthcare provider about your medical condition or your treatment. Be sure to share this important information with members of your household and other caregivers.
What is the most important information I should know about ABSTRAL?
ABSTRAL can cause life-threatening breathing problems which can lead to death.
What is ABSTRAL?
It is not known if ABSTRAL is safe and effective in children under 18 years of age.
Who should not take ABSTRAL?
Do not take ABSTRAL:
What should I tell my healthcare provider before taking ABSTRAL?
Before taking ABSTRAL, tell your healthcare provider if you:
Tell your healthcare provider about all the medicines you take, including prescription and non-prescription medicines, vitamins, and herbal supplements. Some medicines may cause serious or life-threatening side effects when taken with ABSTRAL. Sometimes, the doses of certain medicines and ABSTRAL may need to be changed if used together.
Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.
How should I take ABSTRAL?
Before you can begin to take ABSTRAL:
Taking ABSTRAL:
What should I avoid while taking ABSTRAL?
What are the possible side effects of ABSTRAL?
ABSTRAL can cause serious side effects, including:
These symptoms can be a sign that you have taken too much ABSTRAL or the dose is too high for you. These symptoms may lead to serious problems or death if not treated right away. If you have any of these symptoms, do not take any more ABSTRAL until you have talked to your healthcare provider.
The most common side effects of ABSTRAL are:
Constipation (not often enough or hard bowel movements) is a very common side effect of pain medicines (opioids) including ABSTRAL and is unlikely to go away without treatment. Talk to your healthcare provider about dietary changes, and the use of laxatives (medicines to treat constipation) and stool softeners to prevent or treat constipation while taking ABSTRAL.
Tell your healthcare provider if you have any side effect that bothers you or that does not go away.
These are not all the possible side effects of ABSTRAL. For more information, ask your healthcare provider or pharmacist.
Call your doctor for medical advice about your side effects. You may report side effects to FDA at 1-800FDA-1088.
How should I store ABSTRAL?
How should I dispose of unopened ABSTRAL tablets when they are no longer needed?
General information about ABSTRAL
Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Use ABSTRAL only for the purpose for which it was prescribed. Do not give ABSTRAL to other people, even if they have the same symptoms you have. ABSTRAL can harm other people and even cause death. Sharing ABSTRAL is against the law.
This Medication Guide summarizes the most important information about ABSTRAL. If you would like more information, talk with your healthcare provider or pharmacist. You can ask your pharmacist or healthcare provider for information about ABSTRAL that is written for healthcare professionals.
For more information about the TIRF REMS Access program, go to www.TIRFREMSAccess.com or call 1866-822-1483.
What are the ingredients in ABSTRAL?
Active Ingredient: fentanyl citrate
Inactive Ingredients: croscarmellose sodium, magnesium stearate, mannitol, and silicified microcrystalline cellulose.
Patient Instructions for Use
Before you take ABSTRAL, it is important that you read the Medication Guide and these Patient Instructions for Use. Be sure that you read, understand, and follow these Patient Instructions for Use so that you take ABSTRAL the right way. Ask your healthcare provider or pharmacist if you have questions about the right way to take ABSTRAL.
When you get an episode of breakthrough pain, take the dose prescribed by your healthcare provider as follows:
Manufactured by:
Pharmaceutics International, Inc.
Hunt Valley, MD 21031
Manufactured for:
Galena Biopharma, Inc.
Portland, OR 97239
Issued: November 2014
This Medication Guide has been approved by the U.S. Food and Drug Administration. Copyright © 2013, Galena Biopharma, Inc. All rights reserved.
ABSTRAL and Galena Biopharma are trademarks owned by the Galena Biopharma, Inc.
Principal Display Panel – 100 mcg Carton Label
ABSTRAL®CII
(fentanyl) sublingual tablets
NDC 57881-331-32
Rx only
equivalent to 100 mcg fentanyl base
32 Sublingual Tablets
(4 tablets x 8 cards)
Mfd. by: Pharmaceutics International, Inc., Hunt Valley, MD 21031
Mfd. for: Galena Biopharma Inc., Suite 208, 310 N. State St., Lake Oswego, OR 97034
For questions about ABSTRAL® call: 1-888-ABSTRAL.
Principal Display Panel – 200 mcg Carton Label
ABSTRAL®CII
(fentanyl) sublingual tablets
NDC 57881-332-32
Rx only
equivalent to 200 mcg fentanyl base
32 Sublingual Tablets
(4 tablets x 8 cards)
Mfd. by: Pharmaceutics International, Inc., Hunt Valley, MD 21031
Mfd. for: Galena Biopharma Inc., Suite 208, 310 N. State St., Lake Oswego, OR 97034
For questions about ABSTRAL® call: 1-888-ABSTRAL.
Principal Display Panel – 300 mcg Carton Label
ABSTRAL®CII
(fentanyl) sublingual tablets
NDC 57881-333-32
Rx only
equivalent to 300 mcg fentanyl base
32 Sublingual Tablets
(4 tablets x 8 cards)
Mfd. by: Pharmaceutics International, Inc., Hunt Valley, MD 21031
Mfd. for: Galena Biopharma Inc., Suite 208, 310 N. State St., Lake Oswego, OR 97034
For questions about ABSTRAL® call: 1-888-ABSTRAL.
Principal Display Panel – 400 mcg Carton Label
ABSTRAL®CII
(fentanyl) sublingual tablets
NDC 57881-334-32
Rx only
equivalent to 400 mcg fentanyl base
32 Sublingual Tablets
(4 tablets x 8 cards)
Mfd. by: Pharmaceutics International, Inc., Hunt Valley, MD 21031
Mfd. for: Galena Biopharma Inc., Suite 208, 310 N. State St., Lake Oswego, OR 97034
For questions about ABSTRAL® call: 1-888-ABSTRAL.
Principal Display Panel – 600 mcg Carton Label
ABSTRAL®CII
(fentanyl) sublingual tablets
NDC 57881-336-32
Rx only
equivalent to 600 mcg fentanyl base
32 Sublingual Tablets
(4 tablets x 8 cards)
Mfd. by: Pharmaceutics International, Inc., Hunt Valley, MD 21031
Mfd. for: Galena Biopharma Inc., Suite 208, 310 N. State St., Lake Oswego, OR 97034
For questions about ABSTRAL® call: 1-888-ABSTRAL.
Principal Display Panel – 800 mcg Carton Label
ABSTRAL®CII
(fentanyl) sublingual tablets
NDC 57881-338-32
Rx only
equivalent to 800 mcg fentanyl base
32 Sublingual Tablets
(4 tablets x 8 cards)
Mfd. by: Pharmaceutics International, Inc., Hunt Valley, MD 21031
Mfd. for: Galena Biopharma Inc., Suite 208, 310 N. State St., Lake Oswego, OR 97034
For questions about ABSTRAL® call: 1-888-ABSTRAL.
| RxCUI | RxNorm string | TTY | SPL version |
|---|---|---|---|
| 1053651 | ABSTRAL 100 MCG Sublingual Tablet | PSN | 2 |
| 1053654 | ABSTRAL 200 MCG Sublingual Tablet | PSN | 2 |
| 1053657 | ABSTRAL 300 MCG Sublingual Tablet | PSN | 2 |
| 1053660 | ABSTRAL 400 MCG Sublingual Tablet | PSN | 2 |
| 1053663 | ABSTRAL 600 MCG Sublingual Tablet | PSN | 2 |
| 1053666 | ABSTRAL 800 MCG Sublingual Tablet | PSN | 2 |
| 1053647 | fentaNYL 100 MCG Sublingual Tablet | PSN | 2 |
| 1053652 | fentaNYL 200 MCG Sublingual Tablet | PSN | 2 |
| 1053655 | fentaNYL 300 MCG Sublingual Tablet | PSN | 2 |
| 1053658 | fentaNYL 400 MCG Sublingual Tablet | PSN | 2 |
| 1053661 | fentaNYL 600 MCG Sublingual Tablet | PSN | 2 |
| 1053664 | fentaNYL 800 MCG Sublingual Tablet | PSN | 2 |
| 1053651 | fentanyl 0.1 MG Sublingual Tablet [Abstral] | SBD | 2 |
| 1053654 | fentanyl 0.2 MG Sublingual Tablet [Abstral] | SBD | 2 |
| 1053657 | fentanyl 0.3 MG Sublingual Tablet [Abstral] | SBD | 2 |
| 1053660 | fentanyl 0.4 MG Sublingual Tablet [Abstral] | SBD | 2 |
| 1053663 | fentanyl 0.6 MG Sublingual Tablet [Abstral] | SBD | 2 |
| 1053666 | fentanyl 0.8 MG Sublingual Tablet [Abstral] | SBD | 2 |
| 1053647 | fentanyl 0.1 MG Sublingual Tablet | SCD | 2 |
| 1053652 | fentanyl 0.2 MG Sublingual Tablet | SCD | 2 |
| 1053655 | fentanyl 0.3 MG Sublingual Tablet | SCD | 2 |
| 1053658 | fentanyl 0.4 MG Sublingual Tablet | SCD | 2 |
| 1053661 | fentanyl 0.6 MG Sublingual Tablet | SCD | 2 |
| 1053664 | fentanyl 0.8 MG Sublingual Tablet | SCD | 2 |
| 1053651 | Abstral (as fentanyl citrate) 100 MCG Sublingual Tablet | SY | 2 |
| 1053654 | Abstral (as fentanyl citrate) 200 MCG Sublingual Tablet | SY | 2 |
| 1053657 | Abstral (as fentanyl citrate) 300 MCG Sublingual Tablet | SY | 2 |
| 1053660 | Abstral (as fentanyl citrate) 400 MCG Sublingual Tablet | SY | 2 |
| 1053663 | Abstral (as fentanyl citrate) 600 MCG Sublingual Tablet | SY | 2 |
| 1053666 | Abstral (as fentanyl citrate) 800 MCG Sublingual Tablet | SY | 2 |
| 1053651 | Abstral 0.1 MG Sublingual Tablet | SY | 2 |
| 1053654 | Abstral 0.2 MG Sublingual Tablet | SY | 2 |
| 1053657 | Abstral 0.3 MG Sublingual Tablet | SY | 2 |
| 1053660 | Abstral 0.4 MG Sublingual Tablet | SY | 2 |
| 1053663 | Abstral 0.6 MG Sublingual Tablet | SY | 2 |
| 1053666 | Abstral 0.8 MG Sublingual Tablet | SY | 2 |
| 1053647 | fentanyl (as fentanyl citrate) 100 MCG Sublingual Tablet | SY | 2 |
| 1053652 | fentanyl 200 MCG Sublingual Tablet | SY | 2 |
| 1053655 | fentanyl 300 MCG Sublingual Tablet | SY | 2 |
| 1053658 | fentanyl 400 MCG Sublingual Tablet | SY | 2 |
| 1053661 | fentanyl 600 MCG Sublingual Tablet | SY | 2 |
| 1053664 | fentanyl 800 MCG Sublingual Tablet | SY | 2 |
| Class | Version | Type | Effective |
|---|---|---|---|
| FENTANYL Pharmacologic Class Indexing | 2 | Indexing - Pharmacologic Class | 20180813 |
| Product concept | Relation | Version | Effective |
|---|---|---|---|
| 77d14d2b-b9bf-4254-8dd6-c60dedb281d3 | Product name | 1 | 20231002 |
| a8df478d-5b88-9654-981b-87dff14dda8b | Product name | 2 | 20190801 |
| e9b48db2-e05b-8c2d-e4ac-a5a2efb26b57 | Product name | 2 | 20180118 |
| bb365072-425e-ca0a-021e-fd8b78162502 | Product name | 2 | 20161228 |
| 339915c8-cc8f-ceb4-1d3f-5ea267d21ea6 | Product name | 2 | 20160104 |
| 739fa0ac-b690-63c4-9904-e20dffbf78f9 | Product name | 1 | 20140508 |
| 7763fcbb-367d-ed06-b37f-e1529b6241be | Product name | 1 | 20140508 |
| d9ff6610-5d2e-d5c8-8a19-867d4a1efb77 | Product name | 1 | 20140508 |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 57881-331-04 | Abstral | 4 in 1 BLISTER PACK | TABLET | 4 | 2 | |
| 57881-331-32 | Abstral | 8 in 1 CARTON | TABLET | 8 | 2 | |
| 57881-332-04 | Abstral | 4 in 1 BLISTER PACK | TABLET | 4 | 2 | |
| 57881-332-32 | Abstral | 8 in 1 CARTON | TABLET | 8 | 2 | |
| 57881-333-04 | Abstral | 4 in 1 BLISTER PACK | TABLET | 4 | 2 | |
| 57881-333-32 | Abstral | 8 in 1 CARTON | TABLET | 8 | 2 | |
| 57881-334-04 | Abstral | 4 in 1 BLISTER PACK | TABLET | 4 | 2 | |
| 57881-334-32 | Abstral | 8 in 1 CARTON | TABLET | 8 | 2 | |
| 57881-336-04 | Abstral | 4 in 1 BLISTER PACK | TABLET | 4 | 2 | |
| 57881-336-32 | Abstral | 8 in 1 CARTON | TABLET | 8 | 2 | |
| 57881-338-04 | Abstral | 4 in 1 BLISTER PACK | TABLET | 4 | 2 | |
| 57881-338-32 | Abstral | 8 in 1 CARTON | TABLET | 8 | 2 |
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 57881-331 | ABSTRAL (FENTANYL CITRATE) TABLET [GALENA BIOPHARMA, INC.] | 2 | Legacy NDC, 2 package rows | 20150114_f969e2bc-6297-4e29-89d3-a3685a2c7c6b.zip |
| 57881-332 | ABSTRAL (FENTANYL CITRATE) TABLET [GALENA BIOPHARMA, INC.] | 2 | Legacy NDC, 2 package rows | 20150114_f969e2bc-6297-4e29-89d3-a3685a2c7c6b.zip |
| 57881-333 | ABSTRAL (FENTANYL CITRATE) TABLET [GALENA BIOPHARMA, INC.] | 2 | Legacy NDC, 2 package rows | 20150114_f969e2bc-6297-4e29-89d3-a3685a2c7c6b.zip |
| 57881-334 | ABSTRAL (FENTANYL CITRATE) TABLET [GALENA BIOPHARMA, INC.] | 2 | Legacy NDC, 2 package rows | 20150114_f969e2bc-6297-4e29-89d3-a3685a2c7c6b.zip |
| 57881-336 | ABSTRAL (FENTANYL CITRATE) TABLET [GALENA BIOPHARMA, INC.] | 2 | Legacy NDC, 2 package rows | 20150114_f969e2bc-6297-4e29-89d3-a3685a2c7c6b.zip |
| 57881-338 | ABSTRAL (FENTANYL CITRATE) TABLET [GALENA BIOPHARMA, INC.] | 2 | Legacy NDC, 2 package rows | 20150114_f969e2bc-6297-4e29-89d3-a3685a2c7c6b.zip |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| fentanyl citrate | ACTIVE INGREDIENT | MUN5LYG46H | 2 | |
| fentanyl | ACTIVE MOIETY | UF599785JZ | 2 | |
| cellulose, microcrystalline | INACTIVE INGREDIENT | OP1R32D61U | 2 | |
| croscarmellose sodium | INACTIVE INGREDIENT | M28OL1HH48 | 2 | |
| magnesium stearate | INACTIVE INGREDIENT | 70097M6I30 | 2 | |
| mannitol | INACTIVE INGREDIENT | 3OWL53L36A | 2 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 57881-331 | 57881-331-04, 57881-331-32 |
| 57881-332 | 57881-332-04, 57881-332-32 |
| 57881-333 | 57881-333-04, 57881-333-32 |
| 57881-334 | 57881-334-04, 57881-334-32 |
| 57881-336 | 57881-336-04, 57881-336-32 |
| 57881-338 | 57881-338-04, 57881-338-32 |
Every source-derived ingredient row is available through these pages.
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| mannitol | MANNITOL | 3OWL53L36A | CAPSULE, COATED, EXTENDED RELEASE / ORAL | NA | ||
| magnesium stearate | MAGNESIUM STEARATE | 70097M6I30 | TABLET, CHEWABLE / ORAL | 127 mg | ||
| mannitol | MANNITOL | 3OWL53L36A | GRANULE / ORAL | 1328 mg | ||
| mannitol | MANNITOL | 3OWL53L36A | INJECTION, POWDER, FOR SUSPENSION / INTRAMUSCULAR | 164 mg | ||
| mannitol | MANNITOL | 3OWL53L36A | INJECTION, POWDER, FOR SOLUTION / INTRAMUSCULAR | 300 mg | ||
| mannitol | MANNITOL | 3OWL53L36A | CAPSULE, DELAYED RELEASE / ORAL | 2043 mg | ||
| croscarmellose sodium | CROSCARMELLOSE SODIUM | M28OL1HH48 | INJECTION / INTRAMUSCULAR | 1 %w/v | ||
| cellulose, microcrystalline | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | CAPSULE, EXTENDED RELEASE / ORAL | 1246 mg | ||
| magnesium stearate | MAGNESIUM STEARATE | 70097M6I30 | CAPSULE / ORAL | 256.4 mg | ||
| mannitol | MANNITOL | 3OWL53L36A | INJECTION, SOLUTION / INTRAVENOUS | 15400 mg | ||
| croscarmellose sodium | CROSCARMELLOSE SODIUM | M28OL1HH48 | GRANULE, FOR SUSPENSION / ORAL | 282 mg | ||
| mannitol | MANNITOL | 3OWL53L36A | INJECTION, SUSPENSION, EXTENDED RELEASE / INTRAMUSCULAR | 105 mg | ||
| magnesium stearate | MAGNESIUM STEARATE | 70097M6I30 | SUSPENSION, EXTENDED RELEASE / ORAL | 71 mg | ||
| mannitol | MANNITOL | 3OWL53L36A | TABLET, ORALLY DISINTEGRATING / ORAL | 4364 mg | ||
| mannitol | MANNITOL | 3OWL53L36A | TABLET, DELAYED RELEASE / ORAL | 639 mg | ||
| mannitol | MANNITOL | 3OWL53L36A | POWDER / RESPIRATORY (INHALATION) | 6 mg | ||
| mannitol | MANNITOL | 3OWL53L36A | INJECTION, POWDER, FOR SOLUTION / PARENTERAL | 200 mg | ||
| croscarmellose sodium | CROSCARMELLOSE SODIUM | M28OL1HH48 | TABLET, DELAYED RELEASE PARTICLES / ORAL | 64 mg | ||
| cellulose, microcrystalline | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | TABLET, CHEWABLE / ORAL | 1725 mg | ||
| magnesium stearate | MAGNESIUM STEARATE | 70097M6I30 | TABLET, ORALLY DISINTEGRATING / ORAL | 187 mg | ||
| mannitol | MANNITOL | 3OWL53L36A | SUSPENSION / OPHTHALMIC | 9 mg | ||
| cellulose, microcrystalline | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | POWDER, FOR SOLUTION / ORAL | 690 mg | ||
| mannitol | MANNITOL | 3OWL53L36A | GUM, CHEWING / BUCCAL | 891 mg | ||
| magnesium stearate | MAGNESIUM STEARATE | 70097M6I30 | TABLET, FOR SUSPENSION / ORAL | 131 mg | ||
| mannitol | MANNITOL | 3OWL53L36A | TABLET, COATED / ORAL | 177.7 mg | ||
| cellulose, microcrystalline | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | TABLET, FILM COATED / ORAL | 992 mg | ||
| cellulose, microcrystalline | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | TABLET, CHEWABLE, EXTENDED RELEASE / ORAL | 144 mg | ||
| mannitol | MANNITOL | 3OWL53L36A | INJECTION, POWDER, FOR SUSPENSION / SUBCUTANEOUS | 180 mg | ||
| magnesium stearate | MAGNESIUM STEARATE | 70097M6I30 | INHALANT / ORAL | 0.08 mg | ||
| magnesium stearate | MAGNESIUM STEARATE | 70097M6I30 | TABLET / ORAL | 980 mg | ||
| mannitol | MANNITOL | 3OWL53L36A | TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE / ORAL | 1568 mg | ||
| mannitol | MANNITOL | 3OWL53L36A | SOLUTION, GEL FORMING / DROPS / OPHTHALMIC | 4 mg | ||
| croscarmellose sodium | CROSCARMELLOSE SODIUM | M28OL1HH48 | TABLET / ORAL | 736 mg | ||
| mannitol | MANNITOL | 3OWL53L36A | CAPSULE, EXTENDED RELEASE / ORAL | 160 mg | ||
| magnesium stearate | MAGNESIUM STEARATE | 70097M6I30 | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 53 mg | ||
| magnesium stearate | MAGNESIUM STEARATE | 70097M6I30 | DROPS / ORAL | NA | ||
| cellulose, microcrystalline | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | TABLET, FOR SUSPENSION / ORAL | 20100 mg | ||
| mannitol | MANNITOL | 3OWL53L36A | CONCENTRATE / INTRAVENOUS | 220 mg | ||
| magnesium stearate | MAGNESIUM STEARATE | 70097M6I30 | POWDER, FOR SUSPENSION / ORAL | 120 mg | ||
| mannitol | MANNITOL | 3OWL53L36A | TABLET, EXTENDED RELEASE / ORAL | 1086 mg | ||
| mannitol | MANNITOL | 3OWL53L36A | GEL / OPHTHALMIC | 25 mg | ||
| cellulose, microcrystalline | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | TABLET, EXTENDED RELEASE / ORAL | 5119 mg | ||
| mannitol | MANNITOL | 3OWL53L36A | INJECTION, POWDER, FOR SOLUTION / INTRAVENOUS | 980.4 mg | ||
| mannitol | MANNITOL | 3OWL53L36A | POWDER / ORAL | 4352 mg | ||
| mannitol | MANNITOL | 3OWL53L36A | INJECTION, SUSPENSION / INTRAVENOUS | 2.5 %w/v | ||
| mannitol | MANNITOL | 3OWL53L36A | INJECTION / SUBCUTANEOUS | 675 mg | ||
| mannitol | MANNITOL | 3OWL53L36A | INJECTION / INTRAVENOUS | 15200 mg | ||
| mannitol | MANNITOL | 3OWL53L36A | TABLET, FOR SUSPENSION / ORAL | 7621 mg | ||
| magnesium stearate | MAGNESIUM STEARATE | 70097M6I30 | TABLET, CHEWABLE, EXTENDED RELEASE / ORAL | 9 mg | ||
| cellulose, microcrystalline | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 615 mg | ||
| cellulose, microcrystalline | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | GRANULE, DELAYED RELEASE / ORAL | 789.6 mg | ||
| croscarmellose sodium | CROSCARMELLOSE SODIUM | M28OL1HH48 | TABLET, CHEWABLE / ORAL | 216 mg | ||
| mannitol | MANNITOL | 3OWL53L36A | POWDER, FOR SUSPENSION / ORAL | 7093 mg | ||
| magnesium stearate | MAGNESIUM STEARATE | 70097M6I30 | PELLET / ORAL | 24 mg | ||
| cellulose, microcrystalline | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | CAPSULE / ORAL | 2169 mg | ||
| mannitol | MANNITOL | 3OWL53L36A | TABLET, ORALLY DISINTEGRATING / SUBLINGUAL | 10.25 mg | ||
| mannitol | MANNITOL | 3OWL53L36A | SOLUTION / SUBCUTANEOUS | 4.54 %w/v | ||
| magnesium stearate | MAGNESIUM STEARATE | 70097M6I30 | GRANULE, FOR SUSPENSION / ORAL | 14 mg | ||
| magnesium stearate | MAGNESIUM STEARATE | 70097M6I30 | TABLET / SUBLINGUAL | 17.5 mg | ||
| cellulose, microcrystalline | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | TABLET / ORAL | 6184 mg |
All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| N022510-001 | ABSTRAL | FENTANYL CITRATE | EQ 0.1MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / SUBLINGUAL | RLD | 2011-01-07 | |
| N022510-002 | ABSTRAL | FENTANYL CITRATE | EQ 0.2MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / SUBLINGUAL | RLD | 2011-01-07 | |
| N022510-003 | ABSTRAL | FENTANYL CITRATE | EQ 0.3MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / SUBLINGUAL | RLD | 2011-01-07 | |
| N022510-004 | ABSTRAL | FENTANYL CITRATE | EQ 0.4MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / SUBLINGUAL | RLD | 2011-01-07 | |
| N022510-005 | ABSTRAL | FENTANYL CITRATE | EQ 0.6MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / SUBLINGUAL | RLD | 2011-01-07 | |
| N022510-006 | ABSTRAL | FENTANYL CITRATE | EQ 0.8MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / SUBLINGUAL | RLD | 2011-01-07 |
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-15 13:18:30 | 2026-09 | N022510-001 | ABSTRAL | EQ 0.1MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / SUBLINGUAL | RLD | 2011-01-07 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N022510-002 | ABSTRAL | EQ 0.2MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / SUBLINGUAL | RLD | 2011-01-07 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N022510-003 | ABSTRAL | EQ 0.3MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / SUBLINGUAL | RLD | 2011-01-07 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N022510-004 | ABSTRAL | EQ 0.4MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / SUBLINGUAL | RLD | 2011-01-07 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N022510-005 | ABSTRAL | EQ 0.6MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / SUBLINGUAL | RLD | 2011-01-07 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N022510-006 | ABSTRAL | EQ 0.8MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / SUBLINGUAL | RLD | 2011-01-07 | c2088c7a36db… | |
| 2026-09-14 22:38:34 | 2026-08 | N022510-001 | ABSTRAL | EQ 0.1MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / SUBLINGUAL | RLD | 2011-01-07 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N022510-002 | ABSTRAL | EQ 0.2MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / SUBLINGUAL | RLD | 2011-01-07 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N022510-003 | ABSTRAL | EQ 0.3MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / SUBLINGUAL | RLD | 2011-01-07 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N022510-004 | ABSTRAL | EQ 0.4MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / SUBLINGUAL | RLD | 2011-01-07 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N022510-005 | ABSTRAL | EQ 0.6MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / SUBLINGUAL | RLD | 2011-01-07 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N022510-006 | ABSTRAL | EQ 0.8MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / SUBLINGUAL | RLD | 2011-01-07 | 84e616aacf4f… | |
| 2026-08-18 06:07:40 | 2026-07 | N022510-001 | ABSTRAL | EQ 0.1MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / SUBLINGUAL | RLD | 2011-01-07 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N022510-002 | ABSTRAL | EQ 0.2MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / SUBLINGUAL | RLD | 2011-01-07 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N022510-003 | ABSTRAL | EQ 0.3MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / SUBLINGUAL | RLD | 2011-01-07 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N022510-004 | ABSTRAL | EQ 0.4MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / SUBLINGUAL | RLD | 2011-01-07 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N022510-005 | ABSTRAL | EQ 0.6MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / SUBLINGUAL | RLD | 2011-01-07 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N022510-006 | ABSTRAL | EQ 0.8MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / SUBLINGUAL | RLD | 2011-01-07 | caaa826d4ba7… | |
| 2026-02-19 14:30 UTC | 2026-02 | N022510-001 | ABSTRAL | EQ 0.1MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / SUBLINGUAL | RLD | 2011-01-07 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | N022510-002 | ABSTRAL | EQ 0.2MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / SUBLINGUAL | RLD | 2011-01-07 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | N022510-003 | ABSTRAL | EQ 0.3MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / SUBLINGUAL | RLD | 2011-01-07 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | N022510-004 | ABSTRAL | EQ 0.4MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / SUBLINGUAL | RLD | 2011-01-07 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | N022510-005 | ABSTRAL | EQ 0.6MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / SUBLINGUAL | RLD | 2011-01-07 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | N022510-006 | ABSTRAL | EQ 0.8MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / SUBLINGUAL | RLD | 2011-01-07 | 011fe1cb6892… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N022510-001 | ABSTRAL | EQ 0.1MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / SUBLINGUAL | RLD | 2011-01-07 | 31067a03dcf5… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N022510-002 | ABSTRAL | EQ 0.2MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / SUBLINGUAL | RLD | 2011-01-07 | 31067a03dcf5… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N022510-003 | ABSTRAL | EQ 0.3MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / SUBLINGUAL | RLD | 2011-01-07 | 31067a03dcf5… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N022510-004 | ABSTRAL | EQ 0.4MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / SUBLINGUAL | RLD | 2011-01-07 | 31067a03dcf5… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N022510-005 | ABSTRAL | EQ 0.6MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / SUBLINGUAL | RLD | 2011-01-07 | 31067a03dcf5… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N022510-006 | ABSTRAL | EQ 0.8MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / SUBLINGUAL | RLD | 2011-01-07 | 31067a03dcf5… | |
| 2025-08-23 18:47 UTC | 2025-08 | N022510-001 | ABSTRAL | EQ 0.1MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / SUBLINGUAL | RLD | 2011-01-07 | 6a471c1ec25d… | |
| 2025-08-23 18:47 UTC | 2025-08 | N022510-002 | ABSTRAL | EQ 0.2MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / SUBLINGUAL | RLD | 2011-01-07 | 6a471c1ec25d… | |
| 2025-08-23 18:47 UTC | 2025-08 | N022510-003 | ABSTRAL | EQ 0.3MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / SUBLINGUAL | RLD | 2011-01-07 | 6a471c1ec25d… | |
| 2025-08-23 18:47 UTC | 2025-08 | N022510-004 | ABSTRAL | EQ 0.4MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / SUBLINGUAL | RLD | 2011-01-07 | 6a471c1ec25d… | |
| 2025-08-23 18:47 UTC | 2025-08 | N022510-005 | ABSTRAL | EQ 0.6MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / SUBLINGUAL | RLD | 2011-01-07 | 6a471c1ec25d… | |
| 2025-08-23 18:47 UTC | 2025-08 | N022510-006 | ABSTRAL | EQ 0.8MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / SUBLINGUAL | RLD | 2011-01-07 | 6a471c1ec25d… | |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N022510-001 | ABSTRAL | EQ 0.1MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / SUBLINGUAL | RLD | 2011-01-07 | fd3edfee7708… | |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N022510-002 | ABSTRAL | EQ 0.2MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / SUBLINGUAL | RLD | 2011-01-07 | fd3edfee7708… | |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N022510-003 | ABSTRAL | EQ 0.3MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / SUBLINGUAL | RLD | 2011-01-07 | fd3edfee7708… | |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N022510-004 | ABSTRAL | EQ 0.4MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / SUBLINGUAL | RLD | 2011-01-07 | fd3edfee7708… |
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2019-09-15 20:21 UTC | 2019-09 | N022510-001 | AB | 1 | b00525d2431f… |
| 2019-09-15 20:21 UTC | 2019-09 | N022510-002 | AB | 1 | b00525d2431f… |
| 2019-09-15 20:21 UTC | 2019-09 | N022510-003 | AB | 1 | b00525d2431f… |
| 2019-09-15 20:21 UTC | 2019-09 | N022510-004 | AB | 1 | b00525d2431f… |
| 2019-09-15 20:21 UTC | 2019-09 | N022510-005 | AB | 1 | b00525d2431f… |
| 2019-09-15 20:21 UTC | 2019-09 | N022510-006 | AB | 1 | b00525d2431f… |
| 2019-07-19 19:46 UTC | 2019-07 | N022510-001 | AB | 1 | ea99ee380514… |
| 2019-07-19 19:46 UTC | 2019-07 | N022510-002 | AB | 1 | ea99ee380514… |
| 2019-07-19 19:46 UTC | 2019-07 | N022510-003 | AB | 1 | ea99ee380514… |
| 2019-07-19 19:46 UTC | 2019-07 | N022510-004 | AB | 1 | ea99ee380514… |
| 2019-07-19 19:46 UTC | 2019-07 | N022510-005 | AB | 1 | ea99ee380514… |
| 2019-07-19 19:46 UTC | 2019-07 | N022510-006 | AB | 1 | ea99ee380514… |
| Captured | Edition | Application-product | Patent | Expiration | Use code | Coverage / status | Submission date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|
| 2019-12-13 00:20 UTC | 2019-12 | N022510-001 | 6759059 | 2019-09-24 | U-767 | Drug product | 74a2ff9319b5… | |
| 2019-12-13 00:20 UTC | 2019-12 | N022510-001 | 6761910 | 2019-09-24 | U-767 | Drug product | 74a2ff9319b5… | |
| 2019-12-13 00:20 UTC | 2019-12 | N022510-001 | 7910132 | 2019-09-24 | U-767 | Drug product | 2011-04-01 | 74a2ff9319b5… |
| 2019-12-13 00:20 UTC | 2019-12 | N022510-002 | 6759059 | 2019-09-24 | U-767 | Drug product | 74a2ff9319b5… | |
| 2019-12-13 00:20 UTC | 2019-12 | N022510-002 | 6761910 | 2019-09-24 | U-767 | Drug product | 74a2ff9319b5… | |
| 2019-12-13 00:20 UTC | 2019-12 | N022510-002 | 7910132 | 2019-09-24 | U-767 | Drug product | 74a2ff9319b5… | |
| 2019-12-13 00:20 UTC | 2019-12 | N022510-003 | 6759059 | 2019-09-24 | U-767 | Drug product | 74a2ff9319b5… | |
| 2019-12-13 00:20 UTC | 2019-12 | N022510-003 | 6761910 | 2019-09-24 | U-767 | Drug product | 74a2ff9319b5… | |
| 2019-12-13 00:20 UTC | 2019-12 | N022510-003 | 7910132 | 2019-09-24 | U-767 | Drug product | 74a2ff9319b5… | |
| 2019-12-13 00:20 UTC | 2019-12 | N022510-004 | 6759059 | 2019-09-24 | U-767 | Drug product | 74a2ff9319b5… | |
| 2019-12-13 00:20 UTC | 2019-12 | N022510-004 | 6761910 | 2019-09-24 | U-767 | Drug product | 74a2ff9319b5… | |
| 2019-12-13 00:20 UTC | 2019-12 | N022510-004 | 7910132 | 2019-09-24 | U-767 | Drug product | 74a2ff9319b5… | |
| 2019-12-13 00:20 UTC | 2019-12 | N022510-005 | 6759059 | 2019-09-24 | U-767 | Drug product | 74a2ff9319b5… | |
| 2019-12-13 00:20 UTC | 2019-12 | N022510-005 | 6761910 | 2019-09-24 | U-767 | Drug product | 74a2ff9319b5… | |
| 2019-12-13 00:20 UTC | 2019-12 | N022510-005 | 7910132 | 2019-09-24 | U-767 | Drug product | 74a2ff9319b5… | |
| 2019-12-13 00:20 UTC | 2019-12 | N022510-006 | 6759059 | 2019-09-24 | U-767 | Drug product | 74a2ff9319b5… | |
| 2019-12-13 00:20 UTC | 2019-12 | N022510-006 | 6761910 | 2019-09-24 | U-767 | Drug product | 74a2ff9319b5… | |
| 2019-12-13 00:20 UTC | 2019-12 | N022510-006 | 7910132 | 2019-09-24 | U-767 | Drug product | 74a2ff9319b5… | |
| 2019-12-14 00:12 UTC | 2019-12 | N022510-001 | 6759059 | 2019-09-24 | U-767 | Drug product | 3f01610625f2… | |
| 2019-12-14 00:12 UTC | 2019-12 | N022510-001 | 6761910 | 2019-09-24 | U-767 | Drug product | 3f01610625f2… | |
| 2019-12-14 00:12 UTC | 2019-12 | N022510-001 | 7910132 | 2019-09-24 | U-767 | Drug product | 2011-04-01 | 3f01610625f2… |
| 2019-12-14 00:12 UTC | 2019-12 | N022510-002 | 6759059 | 2019-09-24 | U-767 | Drug product | 3f01610625f2… | |
| 2019-12-14 00:12 UTC | 2019-12 | N022510-002 | 6761910 | 2019-09-24 | U-767 | Drug product | 3f01610625f2… | |
| 2019-12-14 00:12 UTC | 2019-12 | N022510-002 | 7910132 | 2019-09-24 | U-767 | Drug product | 3f01610625f2… | |
| 2019-12-14 00:12 UTC | 2019-12 | N022510-003 | 6759059 | 2019-09-24 | U-767 | Drug product | 3f01610625f2… | |
| 2019-12-14 00:12 UTC | 2019-12 | N022510-003 | 6761910 | 2019-09-24 | U-767 | Drug product | 3f01610625f2… | |
| 2019-12-14 00:12 UTC | 2019-12 | N022510-003 | 7910132 | 2019-09-24 | U-767 | Drug product | 3f01610625f2… | |
| 2019-12-14 00:12 UTC | 2019-12 | N022510-004 | 6759059 | 2019-09-24 | U-767 | Drug product | 3f01610625f2… | |
| 2019-12-14 00:12 UTC | 2019-12 | N022510-004 | 6761910 | 2019-09-24 | U-767 | Drug product | 3f01610625f2… | |
| 2019-12-14 00:12 UTC | 2019-12 | N022510-004 | 7910132 | 2019-09-24 | U-767 | Drug product | 3f01610625f2… | |
| 2019-12-14 00:12 UTC | 2019-12 | N022510-005 | 6759059 | 2019-09-24 | U-767 | Drug product | 3f01610625f2… | |
| 2019-12-14 00:12 UTC | 2019-12 | N022510-005 | 6761910 | 2019-09-24 | U-767 | Drug product | 3f01610625f2… | |
| 2019-12-14 00:12 UTC | 2019-12 | N022510-005 | 7910132 | 2019-09-24 | U-767 | Drug product | 3f01610625f2… | |
| 2019-12-14 00:12 UTC | 2019-12 | N022510-006 | 6759059 | 2019-09-24 | U-767 | Drug product | 3f01610625f2… | |
| 2019-12-14 00:12 UTC | 2019-12 | N022510-006 | 6761910 | 2019-09-24 | U-767 | Drug product | 3f01610625f2… | |
| 2019-12-14 00:12 UTC | 2019-12 | N022510-006 | 7910132 | 2019-09-24 | U-767 | Drug product | 3f01610625f2… | |
| 2019-09-15 20:21 UTC | 2019-09 | N022510-001 | 6759059 | 2019-09-24 | U-767 | Drug product | b00525d2431f… | |
| 2019-09-15 20:21 UTC | 2019-09 | N022510-001 | 6761910 | 2019-09-24 | U-767 | Drug product | b00525d2431f… | |
| 2019-09-15 20:21 UTC | 2019-09 | N022510-001 | 7910132 | 2019-09-24 | U-767 | Drug product | 2011-04-01 | b00525d2431f… |
| 2019-09-15 20:21 UTC | 2019-09 | N022510-002 | 6759059 | 2019-09-24 | U-767 | Drug product | b00525d2431f… |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 621fd88b-b921-47a2-94bd-a778d6005353 | f969e2bc-6297-4e29-89d3-a3685a2c7c6b | 2014-11-30 | Boxed warning, Warnings, Adverse reactions | 621fd88b-b921-47a2-94bd-a778d6005353 f969e2bc-6297-4e29-89d3-a3685a2c7c6b |
Adverse event summaries are temporarily unavailable. Other product information remains available.